HIV Seropositivity Clinical Trial
Official title:
Evaluation of Safety, Efficacy and Acceptability of the PrePexTM Device for Rapid Scale-up of Adult Male Circumcision Programs in Zimbabwe, Phase III PrePexTM Field Implementation Trial With HIV Positive Adult Males
This study will assess the safety of the PrePex device as applied to HIV positive men by assessing the rate of clinical adverse events. The study will include adult, HIV + men who are eligible to receive the PrePex procedure per the Zimbabwe Ministry of Health and Child Care (MOHCC) eligibility criteria.
According to mathematical modeling, Voluntary Medical Male Circumcision (VMMC) has the potential to have a major impact on reducing HIV incidence in areas with high HIV prevalence and low prevalence of male circumcision, as is the case in Zimbabwe. Male circumcision devices have the potential to accelerate VMMC scale-up as the procedure is faster and simpler and can be safely performed by nurses. However, fear of social stigma and desire to avoid HIV testing remain potential barriers to those HIV+ men who would otherwise seek out VMMC. Study subjects (n=400) are HIV+ males who elect to undergo VMMC with PrePex as a study subject, and healthcare workers involved in implementation of PrePex on HIV+ male subjects. The aim of the study is to determine if PrePex can be used safely among HIV+ men with similar rates of adverse events to HIV-uninfected men. If so, then the barrier of mandatory HIV testing as part of VMMC could be removed, encouraging more men to undergo the procedure. Determining PrePex safety in HIV+ men would also allow both those with unknown status and those with positive status to undergo MC with PrePex. Determining the barriers to performing VMMC among HIV+ men among healthcare workers, if any, would also inform future policy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03661203 -
Investigation of the Psychosocial Factors Responsible for the Late Recourse to HIV Testing Within MSM
|
||
Completed |
NCT00381212 -
A Pilot Study to Investigate the Safety and Immunologic Activity AGS-004 an Autologous HIV Immunotherapeutic Agent.
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05983536 -
The Evaluation of Anti-interference Ability and Clinical Specificity of HIV Ag +Ab Assay Kit (Sysmex)
|
||
Recruiting |
NCT04832477 -
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
|
N/A | |
Active, not recruiting |
NCT04044586 -
HIV and HCV Infections in 2 Communes From the Battambang Province, Cambodia: Prevalence Rates, Viral Strains, and Unsafe Injection Practices (12352 ANRS ROK INVEST)
|
||
Active, not recruiting |
NCT00797030 -
Topical Cyclosporine for the Treatment of Dry Eye in Patients Infected With the Human Immunodeficiency Virus
|
Phase 4 | |
Recruiting |
NCT04088916 -
Proviral DNA as a Target for HIV-1 Resistance Analysis
|
||
Completed |
NCT03367130 -
Improving Clinic Attendance for Medication Collection Among HIV Positive Individuals in Nepal
|
N/A | |
Completed |
NCT04849767 -
National Survey About Trajectory and Life Conditions of HIV Trans People in France
|
||
Completed |
NCT05674682 -
Seroincidence Study Among Men Who Have Sex With Men and Transgender Women - The ImPrEP Seroincidence Study
|
N/A | |
Recruiting |
NCT05174234 -
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
|
||
Completed |
NCT00130819 -
Comparison of HIV Clinic-based Treatment With Buprenorphine Versus Referred Care in Heroin-dependent Participants
|
Phase 2 | |
Active, not recruiting |
NCT04706624 -
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
|
N/A | |
Recruiting |
NCT03858478 -
Initiation of First-line Antiretroviral Treatment With TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the First Clinical Contact in France: Trial IMEA 055 - FAST
|
Phase 4 | |
Completed |
NCT02154971 -
Assessment of Age-related Hearing Loss in HIV-1 Patients
|
||
Recruiting |
NCT03311945 -
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
|
Phase 3 | |
Recruiting |
NCT03333083 -
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
|
Phase 3 | |
Recruiting |
NCT03795415 -
ANRS12373 GUNDO SO - Evaluation of an Empowerment Program for WLHIV in Mali
|
||
Completed |
NCT01881971 -
Statins for Pulmonary and Cardiac Complications of Chronic HIV - Coordinating Center
|
Early Phase 1 | |
Completed |
NCT02003989 -
Revealing Increased Axonal Loss in Treated HIV Patients
|
N/A |